The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction

1

Metabolic dysfunction-associated steatohepatitis (MASH) is a significant challenge in hepatology, affecting up to 38% of the adult population globally.
2

MASH progression involves complex interactions between metabolic dysfunction and immune dysregulation, creating a self-perpetuating pathogenic circuit.
3

Immune dysregulation is a principal driver of MASH progression, necessitating immune modulation as a central therapeutic approach.
4

Current therapeutic strategies primarily focus on weight reduction, but some interventions may work through immunomodulatory pathways independent of weight loss.
5

Understanding the hepatic immune landscape is crucial for addressing MASH, as immune cells play complex roles in both disease progression and remission.

1